Clinical trials: Lung Cancer Recurrent
Gastrointestinal Carcinoid Tumor, Islet Cell Tumor
Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors
RATIONALE: Drugs used in chemotherapy, such as fluorouracil, leucovorin, and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Lung Cancer, Neoplastic Syndrome
- Trial name
- NCT00227617
- Testing
- bevacizumab, 5-fluorouracil, leucovorin
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- University of California, San Francisco
Lung Cancer
Palliative Care Teaching Sessions for Family Caregivers of Patients With Non-Small Cell Lung Cancer
RATIONALE: Palliative care teaching sessions may be more effective than standard care in improving caregiver burden, caregiver skills preparedness, quality of life, and distress in family caregivers of patients with non-small…
- Trial name
- NCT00827333
- Testing
- educational intervention, questionnaire administration, end-of-life treatment/management
- Where
- United States
- Volunteers
- 372 people
- Sponsor
- City of Hope Medical Center
Non-small Cell Lung Cancer, Surgery
Anesthesia and Non-small Cell Lung Cancer Recurrence
There has been ongoing debate about the relationship between cancer recurrence and anesthetic management. Therefore, the investigators will test the hypothesis that the recurrence free survival (RFS) after curative resection of…
- Conditions
- Non-small Cell Lung Cancer, Surgery, Anesthesia
- Trial name
- GASTIVA (NCT06330038)
- Testing
- Propofol, Inhaled anesthetics
- Where
- South Korea
- Volunteers
- 5,384 people
- Sponsor
- Samsung Medical Center
Lung Cancer
Cediranib, Paclitaxel, and Carboplatin in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Cediranib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor…
- Trial name
- NCT00795340
- Testing
- carboplatin, cediranib maleate, paclitaxel
- Where
- 19 sites in Brazil, Canada
- Volunteers
- 306 people
- Sponsor
- NCIC Clinical Trials Group
Brain and Central Nervous System Tumors, Breast Cancer
Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer
RATIONALE: Radiolabeled drugs such as yttrium Y 90 SMT 487 can locate tumor cells and deliver tumor-killing substances to them without harming normal cells.
- Conditions
- Brain and Central Nervous System Tumors, Breast Cancer, Gastrointestinal Carcinoid Tumor, Islet Cell Tumor
- Trial name
- NCT00006368
- Testing
- yttrium Y 90-edotreotide
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Novartis Pharmaceuticals
Small-cell Lung Cancer, Relapsed Small Cell Lung Cancer
Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLC
This is a single-arm, phase I/II trial to determine the Maximum Tolerated Dose (MTD), Recommended Phase II Dose (RP2D), and the safety and efficacy of the combination of nivolumab-ipilimumab plus lurbinectedin in patients with…
- Conditions
- Small-cell Lung Cancer, Relapsed Small Cell Lung Cancer, Recurrent Small Cell Lung Cancer
- Trial name
- NCT04610658
- Testing
- Nivolumab, Ipilimumab, Lurbinectedin
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Lung Cancer
Sorafenib and High-Dose Carboplatin, Paclitaxel, and External-Beam Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer
RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00547443
- Testing
- carboplatin, paclitaxel, sorafenib tosylate
- Where
- 2 sites in United States
- Sponsor
- University of Texas Southwestern Medical Center
Lung Cancer
Combination Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00006116
- Testing
- cisplatin, gemcitabine hydrochloride
- Where
- 21 sites in France
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Dyspnea, Respiratory Insufficiency
Cognitive and Behavioral Intervention for the Management of Episodic Breathlessness in Patients With Advanced Disease
Episodic breathlessness is a common and distressing symptom in patients with advanced disease such as cancer, chronic obstructive pulmonary disease (COPD) and chronic heart failure.
- Conditions
- Dyspnea, Respiratory Insufficiency, Neoplasms, Pulmonary Disease, Chronic Obstructive
- Trial name
- CoBeMEB (NCT04630743)
- Testing
- Cognitive and Behavioral intervention for the Management of Episodic Breathlessness
- Where
- Germany
- Volunteers
- 49 people
- Sponsor
- University of Cologne
NSCLC, NSCLC Stage IV
Molecular Landscape Analysis and Clinical Implications for NSCLC Patients With Rare Mutations
Lung cancer is the most common primary cancer of the lung and is responsible for the ever increasing number of cancer-related deaths worldwide.
- Conditions
- NSCLC, NSCLC Stage IV, NSCLC, Recurrent
- Trial name
- NCT05701787
- Where
- 2 sites in China
- Volunteers
- 500 people
- Sponsor
- Shanghai Chest Hospital
Lung Cancer
Nitrocamptothecin in Treating Patients With Recurrent Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of nitrocamptothecin in treating patients who have…
- Trial name
- NCT00005872
- Testing
- rubitecan
- Where
- United States
- Sponsor
- Astex Pharmaceuticals, Inc.
Lung Cancer
Development of a Model to Predict Progression-Free Survival After Erlotinib in Patients With Non-Small Cell Lung Cancer
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00897533
- Testing
- gene mapping, polymorphism analysis, diagnostic laboratory biomarker analysis
- Volunteers
- 137 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Lung Cancer
Gemcitabine With or Without CI-994 in Treating Patients With Advanced Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether gemcitabine plus CI-994 is more effective than gemcitabine alone for non-small…
- Trial name
- NCT00005093
- Testing
- gemcitabine hydrochloride, tacedinaline
- Where
- 16 sites in United States, Canada
- Sponsor
- Pfizer
Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma
Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction
Phase I trial to study the effectiveness of erlotinib in treating patients who have metastatic or unresectable solid tumors and liver or kidney dysfunction.
- Conditions
- Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Anaplastic Oligodendroglioma, Adult Brain Stem Glioma
- Trial name
- NCT00030498
- Testing
- erlotinib hydrochloride, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- National Cancer Institute (NCI)
NSCLC Stage IV, NSCLC, Recurrent
Carboplatin Plus Pemetrexed Plus Atezolizumab Plus Bevacizumab in Chemotherapy and Immunotherapy-naïve Patients With Stage IV Non-squamous Non-small Cell Lung Cancer
This is a multicenter single arm phase II clinical trial. All eligible patients will receive: Carboplatin (AUC 5) i.v. day 1 plus pemetrexed (500 mg/m2) i.v. day 1 plus atezolizumab 1200 mg i.v.
- Trial name
- NCT03713944
- Testing
- Carboplatin, Pemetrexed, Atezolizumab
- Where
- 7 sites in United States
- Volunteers
- 30 people
- Sponsor
- Nasser Hanna
Lung Cancer
Combination Chemotherapy in Treating Patients With Advanced Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00041314
- Testing
- carboplatin, exisulind, gemcitabine hydrochloride
- Where
- 79 sites in United States, Australia and 2 more
- Sponsor
- Eastern Cooperative Oncology Group
Non-Small Cell Lung Cancer
A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC
Evaluate the efficacy and safety of RC108 in combination with Furmonertinib against Furmonertinib for treatment of EGFR mutation combined with MET-positive unresectable locally advanced or recurrent metastatic NSCLC
- Trial name
- NCT06962865
- Testing
- RC108, Furmonertinib Mesilate Tablets Monotherapy
- Where
- 34 sites in China
- Volunteers
- 80 people
- Sponsor
- RemeGen Co., Ltd.
Lung Adenocarcinoma, Lung Cancer
A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib
The purpose of this study is to determine the safety, tolerability and overall response rate of trametinib when given in combination with erlotinib in patients with Stage IV or recurrent lung adenocarcinoma that cannot be treated…
- Conditions
- Lung Adenocarcinoma, Lung Cancer, Lung Cancer Metastatic, Lung Cancer Stage IV
- Trial name
- NCT03076164
- Testing
- Trametinib, Erlotinib
- Where
- 7 sites in United States
- Volunteers
- 24 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Recurrent Extensive Stage Small Cell Lung Carcinoma
HTMC0435 and Temozolomide in Treating Patients With Small Cell Lung Cancer
The Phase 1b part of this clinical trial is to investigate the safety and pharmacokinetic (PK) characteristics of HTMC0435 tablets combined with temozolomide in patients with various advanced solid tumors (recurrent small cell…
- Trial name
- NCT05728619
- Testing
- HTMC0435, Temozolomide
- Where
- 3 sites in China
- Volunteers
- 64 people
- Sponsor
- Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.
Gastrinoma, Glucagonoma
Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors
RATIONALE: Everolimus and vatalanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Conditions
- Gastrinoma, Glucagonoma, Insulinoma, Metastatic Gastrointestinal Carcinoid Tumor
- Trial name
- NCT00655655
- Testing
- everolimus, vatalanib, pharmacological study
- Where
- United States
- Volunteers
- 96 people
- Sponsor
- Mayo Clinic
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.